Proof of the condition is required at the clinic (i.e. referral form, letter from a specialist or primary care provider). All clients should consult their doctor before receiving their third or fourth dose. Please verify any treatment or timing considerations.

For medically eligible; 

  • Third doses may be scheduled a minimum of eight weeks (56 days) after the date of an individual’s second dose. 
  • For individuals 18+ who received a 3 dose primary series, fourth doses/boosters may be scheduled at a minimum of 3 months (84 days) after the third dose. 
  • Individuals re-starting their primary series after receiving chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant, should also consult the vaccine nurse at Lambton Public health. 

Ministry of Health COVID-19 Vaccine Third Dose Recommendations

The above document lists immunosuppressive medications Table:1 (pg5-8). Prescriptions or medication bottles for immunosuppressants listed in the table may be presented for a 3rd dose. If the immunosuppressive medication is not listed, a referral form/ letter for a third dose from a health care provider is required.

  • Referrals must be completed by a health care provider and a copy brought to the clinic

High Risk Health Condition:

  • Individuals receiving active treatment (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumor or hematologic malignancies. Active treatment includes patients who have completed treatment within 3 months.
  • Recipients of solid-organ transplant and taking immunosuppressive therapy.
  • Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy).
  • Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
  • Individuals with Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome.
  • Individuals receiving dialysis (hemodialysis or peritoneal dialysis) 
  • Individuals receiving active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the CIG for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive. Active treatment for patients receiving B-cell depleting therapy includes patients who have completed treatment within 12 months.